A new genome-editing tool from MIT offers great potential for furthering the treatment of diseases. The tool, which combines elements of CRISPR and prime editing, may face difficulty defending it's patent on the non-obviousness standard. “To the extent that there’s patent litigation, I assure you that on the PASTE patent, at least some of those arguments are going to turn on non-obviousness,” he told GEN Edge in their in-depth examination of the new technology.
Read more from GEN Edge.